250 related articles for article (PubMed ID: 33203627)
1. Methotrexate and prednisolone study in erythema nodosum leprosum (MaPs in ENL) protocol: a double-blind randomised clinical trial.
de Barros B; Lambert SM; Shah M; Pai VV; Darlong J; Rozario BJ; Alinda MD; Sales AM; Doni S; Hagge DA; Shrestha D; Listiawan MY; Yitaye AM; Nery JAC; Neupane KD; Dias VLA; Butlin CR; Nicholls PG; Lockwood D; Walker SL
BMJ Open; 2020 Nov; 10(11):e037700. PubMed ID: 33203627
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Efficacy and Safety of Ciclosporin to Prednisolone in the Treatment of Erythema Nodosum Leprosum: Two Randomised, Double Blind, Controlled Pilot Studies in Ethiopia.
Lambert SM; Nigusse SD; Alembo DT; Walker SL; Nicholls PG; Idriss MH; Yamuah LK; Lockwood DN
PLoS Negl Trop Dis; 2016 Feb; 10(2):e0004149. PubMed ID: 26919207
[TBL] [Abstract][Full Text] [Related]
3. Clinico-pathological features of erythema nodosum leprosum: A case-control study at ALERT hospital, Ethiopia.
Negera E; Walker SL; Girma S; Doni SN; Tsegaye D; Lambert SM; Idriss MH; Tsegay Y; Dockrell HM; Aseffa A; Lockwood DN
PLoS Negl Trop Dis; 2017 Oct; 11(10):e0006011. PubMed ID: 29028793
[TBL] [Abstract][Full Text] [Related]
4. The effects of prednisolone treatment on serological responses and lipid profiles in Ethiopian leprosy patients with Erythema Nodosum Leprosum reactions.
Negera E; Tilahun M; Bobosha K; Lambert SM; Walker SL; Spencer JS; Aseffa A; Dockrell HM; Lockwood DN
PLoS Negl Trop Dis; 2018 Dec; 12(12):e0007035. PubMed ID: 30592714
[TBL] [Abstract][Full Text] [Related]
5. Whole blood transcriptomics reveals the enrichment of neutrophil activation pathways during erythema nodosum leprosum reaction.
Rosa TLSA; Leal-Calvo T; Tavares IF; Mendes MA; Dias AA; Piauy MHDS; Barboza MFDS; Kapuscinski M; Costa FDMR; Marques MAM; Belone AFF; Sales AM; Hacker MA; Moreira MBP; Belisle JT; Moraes MO; Pessolani MCV; Schmitz V
Front Immunol; 2024; 15():1366125. PubMed ID: 38715615
[TBL] [Abstract][Full Text] [Related]
6. The mortality associated with erythema nodosum leprosum in Ethiopia: a retrospective hospital-based study.
Walker SL; Lebas E; Doni SN; Lockwood DN; Lambert SM
PLoS Negl Trop Dis; 2014 Mar; 8(3):e2690. PubMed ID: 24625394
[TBL] [Abstract][Full Text] [Related]
7. Increased activated memory B-cells in the peripheral blood of patients with erythema nodosum leprosum reactions.
Negera E; Walker SL; Bekele Y; Dockrell HM; Lockwood DN
PLoS Negl Trop Dis; 2017 Dec; 11(12):e0006121. PubMed ID: 29253897
[TBL] [Abstract][Full Text] [Related]
8. Can baseline ML Flow test results predict leprosy reactions? An investigation in a cohort of patients enrolled in the uniform multidrug therapy clinical trial for leprosy patients in Brazil.
Hungria EM; Oliveira RM; Penna GO; Aderaldo LC; Pontes MA; Cruz R; Gonçalves HS; Penna ML; Kerr LR; Stefani MM; Bührer-Sékula S
Infect Dis Poverty; 2016 Dec; 5(1):110. PubMed ID: 27919284
[TBL] [Abstract][Full Text] [Related]
9. A systematic review on the epidemiological data of erythema nodosum leprosum, a type 2 leprosy reaction.
Voorend CG; Post EB
PLoS Negl Trop Dis; 2013; 7(10):e2440. PubMed ID: 24098819
[TBL] [Abstract][Full Text] [Related]
10. The organization, weaknesses, and challenges of the control of thalidomide in Brazil: A review.
Jesus SM; Santana RS; Leite SN
PLoS Negl Trop Dis; 2020 Aug; 14(8):e0008329. PubMed ID: 32760161
[TBL] [Abstract][Full Text] [Related]
11. Neutrophil NETworking in ENL: Potential as a Putative Biomarker: Future Insights.
Sahu S; Sharma K; Sharma M; Narang T; Dogra S; Minz RW; Chhabra S
Front Med (Lausanne); 2021; 8():697804. PubMed ID: 34336901
[TBL] [Abstract][Full Text] [Related]
12. Erythema nodosum leprosum (type 2 reaction) in a patient with neurofibromatosis type 1.
George R; D'Souza S; Masoodi I
BMJ Case Rep; 2022 Jan; 15(1):. PubMed ID: 34992063
[TBL] [Abstract][Full Text] [Related]
13. Chronic type 2 reaction in lepromatous leprosy with underlying
Sagar HK; Pawar HS
Trop Doct; 2024 Apr; 54(2):182-184. PubMed ID: 37960847
[TBL] [Abstract][Full Text] [Related]
14. Case report: Cyclophosphamide pulse therapy for chronic recalcitrant erythema nodosum leprosum.
Machado GU; Amparo T; Bulhões F; Machado PRL
Front Med (Lausanne); 2023; 10():1272404. PubMed ID: 38020095
[TBL] [Abstract][Full Text] [Related]
15. Erythema nodosum leprosum necroticans: a case report of an atypical severe type 2 leprosy reaction and literature review.
Alfieri A; Dewi ST; Siswati AS; Pudjiati SR; Soebono H
Infez Med; 2024; 32(2):248-253. PubMed ID: 38827837
[TBL] [Abstract][Full Text] [Related]
16. Leprosy Post-Exposure Prophylaxis (LPEP) programme: study protocol for evaluating the feasibility and impact on case detection rates of contact tracing and single dose rifampicin.
Barth-Jaeggi T; Steinmann P; Mieras L; van Brakel W; Richardus JH; Tiwari A; Bratschi M; Cavaliero A; Vander Plaetse B; Mirza F; Aerts A;
BMJ Open; 2016 Nov; 6(11):e013633. PubMed ID: 27856484
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Polymorphisms in Toll-Like Receptor Genes as Biomarkers of the Response to Treatment of Erythema Nodosum Leprosum.
Maciel-Fiuza MF; Costa PDSS; Kowalski TW; Schuler-Faccini L; Bonamigo RR; Vetoratto R; Eidt LM; de Moraes PC; Silveira MIDS; Camargo LMA; Callegari-Jacques SM; Castro SMJ; Vianna FSL
Front Med (Lausanne); 2021; 8():713143. PubMed ID: 35141236
[TBL] [Abstract][Full Text] [Related]
18. Leprosy Reactions: Experience in the Puerto Rico Hansen's Disease Population.
Rodriguez-Rivera DV; Pelet-Del Toro NM; Quintero-Noriega AL
P R Health Sci J; 2023 Sep; 42(3):197-202. PubMed ID: 37709675
[TBL] [Abstract][Full Text] [Related]
19. Analysis of interleukin 7 and platelet-derived growth factor-BB mRNA expression as potential markers in erythema nodosum leprosum.
Bandjar FK; Tabri F; Muchtar SV; Hatta M; Djawad K; Ilyas F; Musafirah S; Massi MN; Bukhari A; Zainuddin AA
Dermatol Reports; 2024 Mar; 16(1):9773. PubMed ID: 38623372
[TBL] [Abstract][Full Text] [Related]
20. Metformin as adjunctive therapy in combination with multidrug treatment for multibacillary leprosy: A protocol for a randomized double-blind, controlled Phase 2 trial in Indonesia (MetLep Trial).
Krismawati H; Muchtar SV; Rahardjani M; Utami NN; Oktaviani M; Puspatriani K; Syamsiah ; Imbiri N; Hasvitasari DE; Fajrianti DR; Tarino N; Wulandari F; Kestelyn E; Du DH; van Crevel R; Walker SL; Geskus RB; Geluk A; Hamers RL; Soebono H; Grijsen ML
Wellcome Open Res; 2023; 8():289. PubMed ID: 38808319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
